Purdue Pharma L.P.
http://www.purduepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Purdue Pharma L.P.
Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
10 Approvals To Look Out For In Q2
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’
FDA advisory committee to consider proposed protocol to meet postmaketing requirement set a decade ago to determine risk of hyperalgesia following long-term use of ER/LA opioid analgesics. Initial trial was terminated in 2018 due to inability to recruit enough patients.
Accord Downs Bankrupt Purdue On Abuse-Deterrent Oxycontin Patents
Intas’ Accord overcame Purdue in Hatch-Waxman litigation involving the originator’s controversial opioid, Oxycontin extended-release.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
- OTC, Consumer
-
Drug Delivery
- Controlled Release
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Imbrium Therapeutics L.P.
- Adlon Therapeutics L.P
- Rhodes Pharmaceuticals LP
- CoCensys Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice